RSS   Newsletter   Contact   Advertise with us
Post Online Media

Veracyte appoints Keith Kennedy as CFO

Keith KennedyVeracyte, a genomic diagnostics company, announced the appointment of Keith Kennedy as chief financial officer, effective December 6, 2016.
Article continues below

READ MORE Veracyte announces changes to its board of directors

Mr. Kennedy joins Veracyte with over 20 years of executive experience in finance.

As president and chief executive officer of MCG Capital, Mr. Kennedy led strategy and operations for the publicly held commercial finance company and assumed various board roles and oversight responsibilities for its portfolio companies in health care and other industries.

He led MCG Capital's successful sale to PennantPark Floating Rate Capital Ltd. in 2015 and consulted for PennantPark Investment Advisors, LLC after the sale.

Mr. Kennedy previously served as MCG's chief financial officer, chief accounting officer and treasurer.

Prior to MCG, he served as a healthcare executive-in-residence at Arlington Capital Partners and a managing director at GE Capital.

Prior to GE Capital, he worked for Ernst & Young LLP and served as an officer in the U.S. Air Force.

Mr. Kennedy received his M.B.A. from The College of William & Mary and Bachelor of Science with high distinction from Indiana University. He is a chartered financial analyst and certified public accountant.

He will succeed Shelly Guyer, who earlier this year announced her plan to step down as CFO and who has continued in the role to ensure a smooth transition.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy